Business Context and Reporting Period
This Form 8-K filing by Oscar Health, Inc. (OSCR) is dated January 27, 2022. The report primarily details the entry into a material definitive agreement for the issuance of convertible senior notes and the announcement of preliminary unaudited financial results for the fiscal year ended December 31, 2021.
Key Financial Metrics and Capital Structure
- Debt Issuance: The Company agreed to sell $305,000,000 in aggregate principal amount of 7.25% Convertible Senior Notes due 2031 to institutional purchasers.
- Liquidity: As of December 31, 2021, the Company held approximately $740 million in cash and cash equivalents at the holding company level.
- Interest Rate: The new Notes bear interest at 7.25% per annum, payable semi-annually in cash.
- Conversion Terms: The initial conversion price is $8.32 per share, representing a 38% premium to the Class A Common Stock price as of January 26, 2022.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or margin figures for the fiscal year 2021, referencing only a press release (Exhibit 99.1) for full details.
Material Changes and Agreements
- Convertible Notes Transaction: The Company entered into an Investment Agreement with Dragoneer Investment Group, Thrive Capital, LionTree, and Tenere Capital. Closing is expected on or around February 3, 2022.
- Standstill Obligations: Purchasers (except Thrive Capital) agreed to a one-year standstill period restricting the acquisition of more than 10% of voting equity, participation in proxy contests, or involvement in acquisition transactions.
- Debt Covenants: The Company is restricted from incurring new indebtedness unless subordinated to the Notes, with a permitted cap of $250 million in aggregate principal amount, provided specific holding thresholds are met by Dragoneer or initial purchasers.
- Credit Agreement Amendment: The Company entered into a First Amendment to its Credit Agreement, obtaining lender consent for the Notes issuance and modifying certain financial maintenance covenants.
Outlook, Risks, and Unusual Items
- Redemption and Repurchase Rights: The Company may not redeem the Notes prior to December 31, 2026. Holders have the right to require repurchase on specific dates starting June 30, 2027, subject to conditions.
- Transfer Restrictions: Purchasers are restricted from transferring, converting, or hedging the Notes for one year or until a change of control, with limited exceptions for affiliates or margin calls.
- Registration Rights: The Company agreed to use reasonable best efforts to amend its Investors' Rights Agreement to provide customary registration rights to Thrive Capital.
- Unusual Items: The filing notes that the financial results included in the press release are not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the final closing date of the $305 million Notes issuance (expected February 3, 2022).
- Review the full text of the Press Release (Exhibit 99.1) for specific revenue, net loss, and member count figures for fiscal year 2021.
- Confirm the specific modifications to financial maintenance covenants in the First Amendment to the Credit Agreement (Exhibit 10.2).
- Monitor the Company's ability to meet the 200% conversion price threshold required for optional redemption after December 31, 2026.
- Assess the impact of the 7.25% interest expense on future cash flows and profitability.